NICE nod for Merck/Pfizer’s Bavencio
Patients in England, Wales and Northern Ireland with a rare and aggressive type of skin cancer will get routine access to a new treatment option on the NHS after cost regulators waved through Merck and Pfizer’s Bavencio.
Read More
